Apnimed's experimental drug reduced breathing interruptions by nearly 46.8% in clinical trials, offering a potential ...

In today’s Health Alert, obstructive sleep apnea may soon be treated with a simple, once-a-day pill. This first-in-class oral ...

Once dismissed as just snoring, sleep apnea is now emerging as an early warning sign for serious conditions like Alzheimer’s, ...

Topline results from a second phase 3 trial of AD109-an investigational oral therapy combining aroxybutynin and ...

Tens of millions of people in the United States struggle with obstructive sleep apnea, a condition that occurs when the ...

Baron Funds, an investment management company, released its “Baron Discovery Fund” second-quarter 2025 investor letter. A ...

(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

A 65-year-old recently retired man presents to the office for his “Welcome to Medicare” exam.The patient retired from his job as an accountant about 3 months ago. His only past medical history, ...

The popular weight-loss and diabetes drugs could play a significant role not only in disease prevention, but possibly in ...

We spoke with endocrinologists to explore the potential of artificial intelligence in the management of chronic disease, including diabetes, obesity, and PCOS.